American biotechnology company Moderna announced Monday that its experimental vaccine for the novel coronavirus has so far shown to be “generally safe and well tolerated” in the first phase of a clinical trial.
The vaccine, mRNA-1273, was the first COVID-19 vaccine candidate to be tested on humans in a clinical trail in the United States. Interim clinical data from phase one of the study also shows that mRNA-1273 produced the same or better antibody levels in participants as convalescent plasma, a century-old technique used for treating epidemics, according to a press release from Moderna.
Enterprise7